id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2026-P-0748-0008,FDA,FDA-2026-P-0748,Completeness Assessment Correspondence,Other,Assessment Document or Analysis,2026-02-25T05:00:00Z,2026,2,2026-02-25T05:00:00Z,,2026-02-25T18:58:57Z,,0,0,09000064b91d83e2
FDA-2026-P-0748-0006,FDA,FDA-2026-P-0748,Suitability Petition Amendment from Senores Phamraceuticals,Other,Amendment,2026-02-09T05:00:00Z,2026,2,2026-02-09T05:00:00Z,,2026-02-09T23:30:42Z,,1,0,09000064b91970f5
FDA-2026-P-0748-0007,FDA,FDA-2026-P-0748,Attachment 4-RLD PI,Supporting & Related Material,Background Material,2026-02-09T05:00:00Z,2026,2,,,2026-02-09T23:30:56Z,,0,0,09000064b91970f7
FDA-2026-P-0748-0001,FDA,FDA-2026-P-0748,"Suitability Petition from Senores Pharmaceuticals, Inc.",Other,Petition(s),2026-01-26T05:00:00Z,2026,1,2026-01-26T05:00:00Z,,2026-02-09T20:18:25Z,,0,0,09000064b91824a7
FDA-2026-P-0748-0005,FDA,FDA-2026-P-0748,Attachment 3 Prescribing Information for Bupropion Hydrochloride,Supporting & Related Material,Background Material,2026-01-26T05:00:00Z,2026,1,,,2026-01-27T02:21:55Z,,0,0,09000064b918312c
FDA-2026-P-0748-0003,FDA,FDA-2026-P-0748,Attachment 1 Orange Book Approved Drug Products with Therapeutic Equivalence Evaluations - WELLBUTRIN (Bupropion Hydrochloride),Supporting & Related Material,Background Material,2026-01-26T05:00:00Z,2026,1,,,2026-01-27T02:21:49Z,,0,0,09000064b91812da
FDA-2026-P-0748-0002,FDA,FDA-2026-P-0748,"Acknowledgement Letter from FDA DMB to Senores Pharmaceuticals, Inc.",Other,Acknowledgement Letter/Receipt,2026-01-26T05:00:00Z,2026,1,2026-01-26T05:00:00Z,,2026-01-27T02:21:43Z,,0,0,09000064b91824a9
FDA-2026-P-0748-0004,FDA,FDA-2026-P-0748,Attachment 2 Prescribing Information for Bupropion Hydrochloride,Supporting & Related Material,Background Material,2026-01-26T05:00:00Z,2026,1,,,2026-01-27T02:21:52Z,,0,0,09000064b91812db